Neuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital
Barcelona, Spain, Düsseldorf, Germany and Paris (ots/PRNewswire) - Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity Neuraxpharm Group ("Neuraxpharm"), the leading European specialty pharmaceutical company focused on ...
mehr